Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
In sickle cell disease (SCD), hydroxyurea (HU) treatment decreases the number of vaso-occlusive crisis (VOC) and acute chest syndrome (ACS) by increasing fetal hemoglobin (HbF). Data are lacking regarding the frequency of HU dose modification or whether sub-therapeutic doses (<15 mg/kg/day) are beneficial. We reviewed the medical records of 140 patients from 2010 to 2014. The laboratory parameters and SCD complications were compared between the first and last visits based on HU use. Fifty patients (36%) never took HU or suspended HU (“no HU” group). Among patients taking <15 mg/kg/day HU on their first visit, half remained at the same dose, and the other half increased to ≥15 mg/kg/day. Among patients taking ≥15 mg/kg/day, 17% decreased to <15 mg/kg/day, and 83% stayed at ≥15 mg/kg/day. The “no HU” group had fewer episodes of VOC and ACS. Both HU treatment groups had a reduction in both complications (p < 0.0001). This improvement was observed in all SCD phenotypes. The white blood cell (WBC) counts were found to be lower, and HbF increased in both HU groups (p = 0.004, 0.001). The maximal HbF response to HU in HbS/β+-thalassemia was 20%, similar to those observed for HbSS (19%) and HbS/β0-thalassemia (22%). HbS/β+-thalassemia could have a similar disease severity as HbSS or HbS/β0-thalassemia. Patients with HbS/β0-thalassemia or HbS/β+-thalassemia phenotypes responded to HU.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In 39 Italian patients with HbSb 1 thalassemia receiving more than 15 mg/kg of hydroxyurea, HbF increased from 4.7% to 10.9%.77”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [77]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320 · cited 10×
“While it was prescribed from 50 to 75% by US hematologists [26,27].”
BackgroundResultInfluentialEffect of hydroxyurea on the frequency of painful crises in sickle cell anemia
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322001 · Cited by 2,340 · cited 2×
“The criteria to start HU treatment were those suggested by Charache et al., 1995 (>3 painful vaso-occlusive crises per year and/or >2 Acute Chest Syndrome [20]).”
BackgroundMethodGlobal epidemiology of haemoglobin disorders and derived service indicators
Modell, B. (2008) · Bulletin of the World Health Organization · doi:10.2471/blt.06.036673 · Cited by 1,924
Piel, F. B., Patil, A. P., Howes, R. E., Nyangiri, O. A., Gething, P. W., Dewi, M., Temperley, W. H., Williams, T. N., Weatherall, D. J., & Hay, S. I. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61229-x · Cited by 1,196 · cited 11×
“%) represented a small proportion of all patients compared to HbS/β0 (39”
BackgroundInfluentialProphylaxis with Oral Penicillin in Children with Sickle Cell Anemia
Gaston, M. H., Verter, J. I., Woods, G., Pegelow, C., Kelleher, J., Presbury, G., Zarkowsky, H., Vichinsky, E., Iyer, R., Lobel, J. S., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606193142501 · Cited by 1,162
Steinberg, M. H., Barton, F., Castro, O., Pegelow, C. H., Ballas, S. K., Kutlar, A., Orringer, E., Bellevue, R., Olivieri, N., Eckman, J., et al. (2003) · JAMA · doi:10.1001/jama.289.13.1645 · Cited by 931
The inherited diseases of hemoglobin are an emerging global health burden
Weatherall, D. J. (2010) · Blood · doi:10.1182/blood-2010-01-251348 · Cited by 903 · cited 1×
“The burden of this and other hemoglobin disorders is expected to increase in the coming decades because of the reductions in infant mortality in many low-income countries and the increasing migration from high- to low-HbS-frequency areas worldwide [4].”
BackgroundKato, G. J., Gladwin, M. T., & Steinberg, M. H. (2007) · Blood Reviews · doi:10.1016/j.blre.2006.07.001 · Cited by 876
Castro, O., Brambilla, D., Thorington, B., Reindorf, C., Scott, R., Gillette, P., Vera, J., & Levy, P. (1994) · Blood · doi:10.1182/blood.v84.2.643.643 · Cited by 808
Wang, W. C., Ware, R. E., Miller, S. T., Iyer, R. V., Casella, J. F., Minniti, C. P., Rana, S., Thornburg, C. D., Rogers, Z. R., Kalpatthi, R. V., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60355-3 · Cited by 803
Castro, O. L., Brambilla, D. J., Thorington, B. D., et al. (1994) · Blood · doi:10.1182/blood.v84.2.643.bloodjournal842643 · Cited by 615
Fetal hemoglobin in sickle cell anemia
Akinsheye, I., Alsultan, A., Solovieff, N., Ngo, D., Baldwin, C. T., Sebastiani, P., Chui, D. H. K., & Steinberg, M. H. (2011) · Blood · doi:10.1182/blood-2011-03-325258 · Cited by 553
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up
Steinberg, M. H., McCarthy, W. F., Castro, O., Ballas, S. K., Armstrong, F. D., Smith, W., Ataga, K., Swerdlow, P., Kutlar, A., DeCastro, L., et al. (2010) · American Journal of Hematology · doi:10.1002/ajh.21699 · Cited by 486 · cited 1×
“Although the long-term use of HU has improved overall survival, it was not clear what proportions of patients were taking a therapeutic dose of ≥15 mg/kg/day [21,22].”
Pulmonary Complications of Sickle Cell Disease
Gladwin, M. T., & Vichinsky, E. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0804411 · Cited by 470
Voskaridou, E., Christoulas, D., Bilalis, A., Plata, E., Varvagiannis, K., Stamatopoulos, G., Sinopoulou, K., Balassopoulou, A., Loukopoulos, D., & Terpos, E. (2010) · Blood · doi:10.1182/blood-2009-05-221333 · Cited by 430 · cited 1×
“The rate of HU administration, in this Caucasian cohort of patients with Sickle-Cell BetaThalassemia, was comparable with the recent papers reporting as HU rate of administration was 50% both in the inpatient cohort of a multi-center study [24] and in the US federal and state insurance-based analysis [25].”
ResultFetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea
Steinberg, M. H., Lu, Z.-H., Barton, F. B., Terrin, M. L., Charache, S., Dover, G. J., & Hydroxyurea, T. M. S. O. (1997) · Blood · doi:10.1182/blood.v89.3.1078 · Cited by 407
Čokić, V. P., Smith, R. D., Beleslin‐Čokić, B. B., Njoroge, J. M., Miller, J. L., Gladwin, M. T., & Schechter, A. N. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16672 · Cited by 375
Hydroxyurea and Sickle Cell Anemia Clinical Utility of a Myelosuppressive “Switching” Agent
Charache, S., Barton, F. B., Moore, R. D., Terrin, M. L., Steinberg, M. H., Dover, G. J., Ballas, S. K., McMahon, R. P., Castro, O., & Orringer, E. P. (1996) · Medicine · doi:10.1097/00005792-199611000-00002 · Cited by 335
Predicting clinical severity in sickle cell anaemia
Steinberg, M. H. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05411.x · Cited by 321 · cited 1×
“, in a cohort of 652 Sickle-Cell Anemia adult patients with heterogeneous descent, suggested as HU treatment was associated with a significant increase in mean total and fetal hemoglobin and a significant decrease in mean white blood and platelet count [32].”
BackgroundFactors associated with survival in a contemporary adult sickle cell disease cohort
Elmariah, H., Garrett, M. E., De Castro, L. M., Jonassaint, J. C., Ataga, K. I., Eckman, J. R., Ashley‐Koch, A. E., & Telen, M. J. (2014) · American Journal of Hematology · doi:10.1002/ajh.23683 · Cited by 300 · cited 2×
“Hydroxyurea (HU) has been approved for treating SCD [11].”
BackgroundSickle cell disease related mortality in the United States (1999-2009)
Hamideh, D., & Alvarez, O. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24557 · Cited by 290 · cited 1×
“The median age of death was reported to be 42 years for men and 48 years for women [9,10].”
BackgroundHydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial
Ferster, A., Vermylen, C., Cornu, G., Buyse, M., Corazza, F., Devalck, C., Fondu, P., Toppet, M., & Sariban, E. (1996) · Blood · doi:10.1182/blood.v88.6.1960.bloodjournal8861960 · Cited by 279 · cited 1×
“Although the long-term use of HU has improved overall survival, it was not clear what proportions of patients were taking a therapeutic dose of ≥15 mg/kg/day [21,22].”
BackgroundHalasa, N. B., Shankar, S. M., Talbot, T. R., Arbogast, P. G., Mitchel, E. F., Wang, W. C., Schaffner, W., Craig, A. S., & Griffin, M. R. (2007) · Clinical Infectious Diseases · doi:10.1086/516781 · Cited by 253
Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease
Gladwin, M. T., Shelhamer, J. H., Ognibene, F. P., Pease‐Fye, M. E., Nichols, J. S., Link, B., Patel, D. B., Jankowski, M. A., Pannell, L. K., Schechter, A. N., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03274.x · Cited by 234
Discontinuing penicillin prophylaxis in children with sickle cell anemia
Falletta, J. M., Woods, G. M., Verter, J. I., Buchanan, G. R., Pegelow, C. H., Iyer, R. V., Miller, S. T., Holbrook, C. T., Kinney, T. R., Vichinsky, E., et al. (1995) · The Journal of Pediatrics · doi:10.1016/s0022-3476(95)70154-0 · Cited by 207
Advances in the use of hydroxyurea
Ware, R. E., & Aygun, B. (2009) · Hematology · doi:10.1182/asheducation-2009.1.62 · Cited by 142
Benkerrou, M., Delarche, C., Brahimi, L., Fay, M., Vilmer, E., Elion, J., Gougerot-Pocidalo, M.-A., & Elbim, C. (2002) · Blood · doi:10.1182/blood.v99.7.2297 · Cited by 110
Current Management of Sickle Cell Anemia
McGann, P. T., Nero, A. C., & Ware, R. E. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011817 · Cited by 63
Rigano, P., Franceschi, L. D., Sainati, L., Piga, A. G., Piel, F. B., Cappellini, M. D., Fidone, C., Masera, N., Palazzi, G., Gianesin, B., et al. (2017) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2017.08.017 · Cited by 63
Self-citationWang, W., Brugnara, C., Snyder, C., Wynn, L., Rogers, Z., Kalinyak, K., Brown, C., Qureshi, A., Bigelow, C., Neumayr, L., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08523.x · Cited by 42 · cited 1×
“The rate of HU administration, in this Caucasian cohort of patients with Sickle-Cell BetaThalassemia, was comparable with the recent papers reporting as HU rate of administration was 50% both in the inpatient cohort of a multi-center study [24] and in the US federal and state insurance-based analysis [25].”
ResultHydroxyurea induction of fetal hemoglobin synthesis in sickle-cell disease.
Dover, G. J., & Charache, S. (1992) · PubMed · Cited by 26
In vitro induction of fetal hemoglobin in human erythroid progenitor cells
Ho, J. A., Pickens, C. V., Gamscik, M. P., Colvin, O. M., & Ware, R. E. (2003) · Experimental Hematology · doi:10.1016/s0301-472x(03)00086-9 · Cited by 18
Sickle Cell Anemia and Fetal Hemoglobin
Steinberg, M. H. (1994) · The American Journal of the Medical Sciences · doi:10.1097/00000441-199411000-00001 · Cited by 12
Hydroxyurea Therapy Reduces Mortality Among Children with Sickle Cell Disease
Lobo, C. L. D. C., Hankins, J. S., de Moura, P. G., & Pinto, J. F. D. C. (2010) · Blood · doi:10.1182/blood.v116.21.843.843 · Cited by 11 · cited 1×
“While it was prescribed from 50 to 75% by US hematologists [26,27].”
Background
Cited by
Fetal hemoglobin in sickle cell anemia
Steinberg, M. H. (2020) · Blood · doi:10.1182/blood.2020007645 · Cited by 136
Bou‐Fakhredin, R., Franceschi, L. D., Motta, I., Cappellini, M. D., & Taher, A. T. (2022) · Pharmaceuticals · doi:10.3390/ph15060753 · Cited by 64
Russo, G. M., Franceschi, L. D., Colombatti, R., Rigano, P., Perrotta, S., Voi, V., Palazzi, G., Fidone, C., Quota, A., Graziadei, G., et al. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1099-0 · Cited by 59
Self-citationYasara, N., Premawardhena, A., & Mettananda, S. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01757-w · Cited by 60
“Similarly, patients with sickle β-thalassaemia and SCA demonstrated comparable HbF responses of 20% and 19% respectively to hydroxyurea [73].”
BackgroundGlomerular filtration rate abnormalities in sickle cell disease
Afangbedji, N. K. A., & Jerebtsova, M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1029224 · Cited by 31
“Hydroxyurea treatment increases HbF levels (65, 66) and is recommended for almost all patients with HbSS and HbSβ0 disease starting in the first year of life.”
Background
Metadata
- Authors
- Di Maggio, R., Hsieh, M., Zhao, X., Calvaruso, G., Rigano, P., Renda, D., Tisdale, J., & Maggio, A.
- Affiliations
- Campus of Haematology Franco and Piera Cutino, AOOR Villa Sofia-V. Cervello, 90142 Palermo, Italy
- National Institute of Diabetes and Digestive and Kidney Diseases (US)
- National Institutes of Health (US)
- Ospedale Vincenzo Cervello (IT)
- Corresponding author
- Maggio, Aurelio
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2018-02-28
- Volume
- 19
- Issue
- 3
- Pages
- 681
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC5877542
- OpenAlex
- W2791021987
- Semantic Scholar
- 80384dfdf2ceddb6ce7dc18132aca3830b44b35f
- Cited by
- 12
- References
- 33
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 1 · 2022: 2 · 2021: 3 · 2020: 2 · 2019: 1
- FWCI
- 0.85
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Hematology › Blood groups and transfusion
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Keywords
- hydroxyurea, sickle cell disease, sickle beta-thalassemia, vaso-occlusive crisis, acute chest syndrome, fetal hemoglobin, HbSS, white blood cell count
- MeSH terms
- Adolescent, Adult, Anemia, Sickle Cell, Antisickling Agents, Child, Child, Preschool, Erythrocyte Indices, Female, Follow-Up Studies, Heart Function Tests, Humans, Hydroxyurea, Infant, Liver Function Tests, Male, Middle Aged, Phenotype, Treatment Outcome, beta-Thalassemia, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
